Results 241 to 250 of about 1,610,894 (277)

Dynamic Collaborations for the Development of Immune Checkpoint Blockade Agents [PDF]

open access: yesJournal of Personalized Medicine, 2021
We studied the overview of drug discovery and development to understand the recent trends and potential success factors of interorganizational collaboration by reviewing 1204 transactions performed until 2019 for 107 anticancer drugs approved by the US Food and Drug Administration (FDA) from 1999 to 2018.
Shintaro Sengoku   +2 more
exaly   +3 more sources

Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective

Journal of Cancer Research and Clinical Oncology, 2021
CD47, a transmembrane protein, acts as a "do not eat me" signal that is overexpressed in many tumor cell types, thereby forming a signaling axis with its ligand signal regulatory protein alpha (SIRPα) and enabling the tumor cells to escape from macrophage-mediated phagocytosis.
Yu-Chi Chen   +3 more
openaire   +2 more sources

Tumour-Intrinsic Resistance to Immune Checkpoint Blockade [PDF]

open access: yesNature Reviews Immunology, 2020
'Immune checkpoint blockade' for cancer describes the use of therapeutic antibodies that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour immune responses.
Anusha Kalbasi, Antoni Ribas
exaly   +2 more sources

The prognostic impact of immune-related adverse events in real-world patients with metastatic melanoma treated with single-agent and combination immune checkpoint blockade.

Journal of Clinical Oncology, 2022
9542 Background: Immune checkpoint blockade (ICB) has revolutionized the treatment of metastatic melanoma (MM). Immune-related Adverse Events (irAEs) associated with ICB have been shown to correlate positively with survival outcomes across solid tumours.
Alexander Watson   +11 more
openaire   +1 more source

Abstract 2947: Preclinical evaluation of a novel B7-H4 targeted antibody-drug conjugate AZD8205 as a single agent and in combination with novel PARP inhibitor and checkpoint blockade

Cancer Research, 2023
Abstract B7-H4 is a cell-surface protein overexpressed in several tumor types and is most prevalent in triple-negative breast (TNBC) cancer (74%), ovarian carcinoma (77%), endometrial carcinoma (94%), and cholangiocarcinoma (89%). In contrast, it has a limited expression in normal tissue, making it an attractive target for an antibody ...
Alex Cazes   +19 more
openaire   +1 more source

Engineered Microglia‐Exosomes Coated Highly Twisting AIE Photothermal Agents to Efficiently Cross Blood‐Brain‐Barrier for Mild Photothermal‐Immune Checkpoint Blockade Therapy in Glioblastoma

Advanced Functional Materials, 2023
Abstract Immune checkpoint blockade (ICB) therapy has achieved remarkable therapeutic effects in cancer, but it is not effective in glioblastoma (GBM). The main reason is that it is difficult for drugs to penetrate blood‐brain‐barrier (BBB) to GBM and lacks enough pre‐existing cytotoxic CD8 +
Xun Lin   +13 more
openaire   +1 more source

Brain metastases in patients with pleural mesothelioma receiving dual checkpoint blockade compared to single-agent checkpoint blockade or chemotherapy.

Journal of Clinical Oncology
e20093 Background: Immunotherapy (IO) has emerged as a treatment option in pleural mesothelioma (PM). Historically, brain metastases (BM) in PM were rare, thus brain imaging is not routine practice or included in guidelines. We characterize the incidence of BMs by type of treatment received. Methods: In this retrospective analysis,adult patients with
Margaret Stalker   +11 more
openaire   +1 more source

Abstract 2399: LAG-3/PD-L1 mAb2 can overcome PD-L1-mediated compensatory upregulation of LAG-3 induced by single-agent checkpoint blockade

Cancer Research, 2019
Abstract FS118, currently tested in Phase I clinical trial in patients with advanced malignancies (NCT03440437), is a first-in-class bispecific antagonistic antibody (known as mAb2) targeting LAG-3 (Lymphocyte-Activation Gene 3) and PD-L1 (Programmed Death-Ligand 1), two immune checkpoint molecules that promote tumour escape from immune ...
Mustapha Faroudi   +10 more
openaire   +1 more source

Abstract 4607: Specific inhibition of PGE2-EP4 signaling by E7046 promotes anti-tumor activity of checkpoint blockade agents through boosting cytotoxic T cell activity

Cancer Research, 2017
Abstract Purpose: Immunotherapies targeting immune checkpoint receptors have shown great promise for a subset of cancer patients; however, robust and safe combination therapies are still needed. In the tumor microenvironment, prostaglandin E2 receptor type 4 (EP4) signaling has been implicated in both protumoral myeloid cell ...
Diana I. Albu   +11 more
openaire   +1 more source

Home - About - Disclaimer - Privacy